Hsbc Holdings PLC Cuts Stake in Edwards Lifesciences Corporation $EW

Hsbc Holdings PLC lessened its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 8.4% in the 2nd quarter, Holdings Channel.com reports. The firm owned 1,569,398 shares of the medical research company’s stock after selling 144,364 shares during the quarter. Hsbc Holdings PLC’s holdings in Edwards Lifesciences were worth $141,949,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. BlackRock Inc. purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $5,318,092,000. Bank of New York Mellon Corp bought a new position in Edwards Lifesciences in the second quarter worth about $1,274,082,000. Norges Bank bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $803,686,000. Deutsche Bank AG acquired a new position in shares of Edwards Lifesciences during the second quarter worth $516,552,000. Finally, Legal & General Group Plc acquired a new position in Edwards Lifesciences during the 2nd quarter valued at about $389,089,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Up 0.5%

Shares of NYSE EW opened at $90.92 on Wednesday. The firm has a market cap of $52.35 billion, a price-to-earnings ratio of 52.25, a price-to-earnings-growth ratio of 2.37 and a beta of 0.85. The company’s 50-day simple moving average is $89.35 and its 200-day simple moving average is $84.82. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Activity

In related news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 2,425 shares of company stock valued at $219,199. 0.31% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

EW has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Mizuho upped their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. UBS Group assumed coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They set a “buy” rating and a $110.00 price target for the company. BTIG Research boosted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Finally, Truist Financial increased their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.